相关实验视频
Updated: Jan 27, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
958
贝图林激活肝脏PPARα-FGF21信号传递以对抗肥胖
Lulu Ma1, Tengteng Huang1, Xihao Luo1
1Animal Nutrition Institute, Sichuan Agricultural University, Chengdu 611130, China.
Journal of agricultural and food chemistry
|January 25, 2026
概括
贝图林是一种天然化合物,通过激活PPARα通路来对抗肥胖,从而增加FGF21的产生. 这种机制提高了葡萄糖耐受性,减少了肝脏脂肪,为代谢障碍治疗提供了新的希望.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 肥胖研究的研究.
- 自然产品药理学 自然产品药理学
背景情况:
- 贝图林是一种五环三基,在代谢障碍方面表现有前途.
- 它的精确作用机制,特别是在肥胖症中,尚未完全理解.
研究的目的:
- 在高脂肪饮食诱导的肥胖小鼠模型中研究贝图林的代谢作用.
- 阐明调解贝林作用的分子通路,重点关注肝脏基因表达和信号传递.
主要方法:
- 在食高脂肪饮食的小鼠中服用贝林食补充剂.
- 肝转录组学用于分析基因表达变化.
- 分子动力学模拟和实验验证,以确认分子相互作用.
主要成果:
- 贝图林补充剂减少了体重增加,改善了葡萄糖耐受性和减少了肝脏脂质积累.
- 肝转录学确定过氧体增殖器激活受体-α (PPARα) 途径和纤维细胞生长因子21 (FGF21) 作为关键标.
- 贝图林被证实作为PPARα激动剂,诱导FGF21表达体内和体外.
结论:
- 贝图林作为PPARα激动剂,导致FGF21表达增加,并赋予代谢益处.
- 这项研究阐明了一种新的肝激素依赖途径,用于贝林的抗肥胖和抗代谢障碍作用.
相关概念视频
Obesity
1.2K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
221
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
221
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
267
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
267
Drug Dosing: Obese Patients
238
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
238
Hepatic Portal System
5.7K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K
Endocrine Signaling
68.0K
Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
68.0K

